OncoMatch/Clinical Trials/NCT06178614

A Study of JNJ-87890387 for Advanced Solid Tumors

Is NCT06178614 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JNJ-87890387 for neoplasms.

Phase 1RecruitingJanssen Research & Development, LLCNCT06178614Data as of May 2026

Treatment: JNJ-87890387 — The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Start Midwest · Grand Rapids, Michigan
Sarah Cannon Research Institute · Nashville, Tennessee

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify